Good article. It would be nice if a lot more people looked at the company as a whole and not just keep comparing Lumia to iPhone for value of the company. That's what it seems to be like at this point.
I am a phone fanatic. My buddy is an app developer and has had ios6 for about 3 months (beta version). Ios6 is pretty smooth. It actually has great features by way of convenience. The market, and I, were definitely expecting something to WOW us!! This phone will sell like crazy as does every upgrade to any Apple product. But, I remember being sick to my stomach when the 4s came out! Not that many upgrades to make a HUGE difference. Of course it sold like crazy. The 5? Bigger screen, faster processor, better camera? Evolutionary, not revolutionary. Disagree all you want, but it's true. A faster, better phone, with a bigger screen is like buying a nicer model of a vehicle. And the body change is like new headlights. Bigger screen, lighter weight and brighter screen are not a total model change. They are upgrades. P.S I do own Apple stock and all Apple products. So, not really talking bad or good on the product, just my opinion.
More on Nokia: The company has also received another bearish note from Bernstein's Pierre Ferragu, a long-time critic. Ferragu joins others in taking a cautious view of the impact of the Apple-Samsung verdict; thinks Q3 results could miss estimates; notes Lumia models are being heavily discounted in the UK, and says global surveys have consistently shown a "lack of consumer interest" in Windows Phone. He views Nokia's recent rally as a good shorting opportunity. [View news story]
Amazing how this guy can say something like this and watch it work to his advantage. I bet he made millions this morning.
The FDA votes 18-4-1 to recommend Arena Pharmaceutical's (ARNA) weight loss drug lorcaserin to the FDA regulators for approval or rejection. Shares currently halted. [View news story]
Nokia Will Outperform Apple [View article]
Apple: One More Thing [View article]
More on Nokia: The company has also received another bearish note from Bernstein's Pierre Ferragu, a long-time critic. Ferragu joins others in taking a cautious view of the impact of the Apple-Samsung verdict; thinks Q3 results could miss estimates; notes Lumia models are being heavily discounted in the UK, and says global surveys have consistently shown a "lack of consumer interest" in Windows Phone. He views Nokia's recent rally as a good shorting opportunity. [View news story]
The FDA votes 18-4-1 to recommend Arena Pharmaceutical's (ARNA) weight loss drug lorcaserin to the FDA regulators for approval or rejection. Shares currently halted. [View news story]